ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMGastos comerciales, generales y administrativos148.03 M133.67 M137.78 M138.52 M143.37 M143.57 M563.24 MInvestigación y desarrollo43.31 M37.88 M47.19 M48.58 M52.12 M58.7 M206.58 MBeneficio operativo37.02 M48.62 M54.18 M54.01 M42.58 M41.47 M192.24 MTotal de ingresos no operativos35.23 M3.15 M-4.25 M-7.49 M-2.35 M-5.7 M-19.79 MGastos por intereses, netos de intereses capitalizados15.77 M15.29 M12.28 M10.86 M10.86 M8.29 M42.29 MIngresos no operativos, una vez deducidos los gastos por intereses34.22 M-12.07 M-16.73 M-18.76 M-13.34 M-14.08 M-62.92 MIngresos/gastos extraordinarios1 M-73 K200 K400 K137 K98 K835 KBeneficio antes de impuestos56.48 M-315.67 M33.31 M33.9 M27.62 M26.63 M121.47 MParticipación en los beneficios0-20 K-8 000-13 K-10 K-851 K-882 KImpuestos589 K11.66 M6.15 M7.11 M-3.28 M4.34 M14.32 MParticipación minoritaria———————Otros ingresos/gastos después de impuestos-1.5 M-11 K-957 K-1.46 M-761 K-1.17 M-4.35 MBeneficio neto antes de actividades interrumpidas55.89 M-327.32 M27.16 M26.78 M30.91 M22.29 M107.14 MOperaciones suspendidas———————Beneficio neto55.89 M-327.32 M27.16 M26.78 M30.91 M22.29 M107.14 MAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas55.89 M-327.32 M27.16 M26.78 M30.91 M22.29 M107.14 MBeneficio básico por acción1.04-6.010.50.490.570.411.97Beneficio por acción diluido1.04-6.010.50.490.570.41.96Número medio de acciones ordinarias54.24 M54.42 M54.58 M54.63 M54.55 M54.69 M—Acciones diluidas54.57 M54.42 M54.71 M55.15 M54.55 M55.94 M—EBITDA39.39 M-299.07 M64.92 M69.63 M56.06 M54.55 M245.16 MEBIT22.82 M-315.38 M43.69 M42.83 M25.02 M36.92 M148.46 MCosto de los ingresos90.07 M96.08 M113.54 M112.9 M121.15 M118.51 M466.09 MOtros costes de producción———————Amortización y depreciación (flujo de caja)16.57 M16.31 M21.23 M26.8 M31.04 M17.63 M96.7 M
LivaNova PLC - Ordinary Shares
LivaNova, plc is a medical device manufacturer that is a foreign domiciled company based in the U.K. for tax inversion purposes. With operational headquarters in the United States. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".